home / stock / vinc / vinc quote
Last: | $0.737 |
---|---|
Change Percent: | 1.22% |
Open: | $0.75 |
Close: | $0.737 |
High: | $0.7995 |
Low: | $0.73 |
Volume: | 275,234 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.737 | $0.75 | $0.737 | $0.7995 | $0.73 | 275,234 | 07-02-2024 |
$0.7593 | $0.814 | $0.7593 | $0.8586 | $0.7091 | 354,899 | 07-01-2024 |
$0.81 | $0.681 | $0.81 | $0.8378 | $0.6501 | 658,281 | 06-28-2024 |
$0.74 | $0.5969 | $0.74 | $0.748 | $0.576 | 994,933 | 06-27-2024 |
$0.59 | $0.587 | $0.59 | $0.5909 | $0.575 | 48,488 | 06-26-2024 |
$0.5739 | $0.6 | $0.5739 | $0.605143 | $0.5739 | 96,253 | 06-25-2024 |
$0.5917 | $0.59 | $0.5917 | $0.615 | $0.5684 | 107,668 | 06-24-2024 |
$0.6 | $0.6021 | $0.6 | $0.6345 | $0.6 | 227,233 | 06-21-2024 |
$0.601 | $0.6127 | $0.601 | $0.6325 | $0.6005 | 138,394 | 06-20-2024 |
$0.6 | $0.6529 | $0.6 | $0.6529 | $0.6 | 201,708 | 06-19-2024 |
$0.6 | $0.6529 | $0.6 | $0.6529 | $0.6 | 201,708 | 06-18-2024 |
$0.6461 | $0.6745 | $0.6461 | $0.6793 | $0.63 | 200,940 | 06-17-2024 |
$0.6794 | $0.72 | $0.6794 | $0.7247 | $0.6702 | 120,506 | 06-14-2024 |
$0.6889 | $0.71 | $0.6889 | $0.72 | $0.6801 | 115,935 | 06-13-2024 |
$0.723 | $0.7362 | $0.723 | $0.7362 | $0.7 | 211,846 | 06-12-2024 |
$0.7367 | $0.72 | $0.7367 | $0.749 | $0.65 | 229,296 | 06-11-2024 |
$0.7154 | $0.712 | $0.7154 | $0.7316 | $0.695 | 108,748 | 06-10-2024 |
$0.712 | $0.71 | $0.712 | $0.7299 | $0.68 | 158,725 | 06-07-2024 |
$0.7211 | $0.725 | $0.7211 | $0.7427 | $0.7 | 165,484 | 06-06-2024 |
$0.7398 | $0.6477 | $0.7398 | $0.7584 | $0.63 | 381,808 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Vincera Pharma Inc Com Company Name:
VINC Stock Symbol:
NASDAQ Market:
Vincera Pharma Inc Com Website:
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive result...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warra...